– Management Hosting Webcast of Key Opinion Leader Discussion Today at 6:00 p.m. ET –
CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today presents updated data from NT-001, its ongoing Phase 1b clinical trial evaluating NEO-PV-01 in the metastatic setting, and new data relating to its NEO-PTC-01 program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting in Washington, D.C.
NEO-PV-01 is a personal neoantigen vaccine custom-designed and manufactured based on the unique mutational fingerprint of each individual patient. NEO-PTC-01 is a personal neoantigen T cell therapy consisting of multiple T cell populations targeting what are believed to be the most therapeutically relevant neoantigen from each patient’s tumor.
“We are pleased to have Siwen Hu-Lieskovan M.D., Ph.D., a clinical investigator from the David Geffen School of Medicine at the University of California, Los Angeles, present data from our NT-001 Phase 1b study focusing on detailed patient vignettes from the study. These vignettes of patients treated with NEO-PV-01 and nivolumab demonstrate immunological changes in the blood and tumor that correlate with clinical responses. We continue to be encouraged by the breadth and depth of these findings in the challenging metastatic setting,” said Richard Gaynor, President of Research and Development of Neon Therapeutics. “In addition, we are excited to be presenting new data that gives us added confidence in NEO-PTC-01. For the first time using patient materials, we demonstrate that NEO-STIM™, our proprietary ex vivo co-culture process using peripheral blood mononuclear cells, can reliably and reproducibly generate multiple enriched neoantigen-specific T cell populations that are capable of killing tumor cells. We look forward to submitting the CTA filing for NEO-PTC-01 during the first half of 2019.”
Details regarding these results will be made available on the “Investors” section of the Neon website at ir.neontherapeutics.com following Dr. Hu-Lieskovan’s presentation.
Investor Event and Webcast Information
Neon Therapeutics will host a live webcast today at 6:00 p.m. ET featuring a keynote presentation from Dr. Siwen Hu-Lieskovan, Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles. To access the live webcast, please visit the Investor Relations section of Neon’s website at ir.neontherapeutics.com. A replay of the webcast will be posted shortly after the conference call and will remain available for 30 days following the call.
About NT-001
NT-001 is a Phase 1b study evaluating NEO-PV-01 in combination with nivolumab in both checkpoint naïve first and later-line treated patients with metastatic melanoma, smoking-associated, non-small cell lung cancer (NSCLC) or bladder cancer. The primary endpoint of the study is safety. Exploratory endpoints include both neoantigen-specific immune responses as well as post-vaccine clinical responses, clinical response durability and correlation between immune and clinical findings.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer. For more information, please visit www.neontherapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of Neon Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the potential timing and advancement of our preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; and our expectations regarding our uses of capital, expenses, future accumulated deficit and other 2018 financial results; and our ability to fund operations through at least the first quarter of 2020. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to protect and maintain our intellectual property position; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies and clinical trials will be predictive of future results in connection with future studies or trials; and the risk that Neon’s collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Neon’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Neon’s most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Neon’s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Neon undertakes no duty to update this information unless required by law.
Media Contact:
Stephanie Simon, Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
Investor Contact:
Will O’Connor, Stern Investor Relations
will@sternir.com
212-362-1200